View Older Stories View More Recent Stories

Nov 18, 2024 07:00AM PreveCeutical's Subsidary, Biogene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer
Nov 15, 2024 02:49PM PreveCeutical Announces Closing of BioGene Therapeutics Transaction
Nov 13, 2024 07:00AM PreveCeutical's Subsidiary, BioGene Therapeutics, Appoints President
Oct 30, 2024 06:30AM PreveCeutical Launches Strategic Partnership with BioGene Therapeutics
Oct 18, 2024 02:46PM PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services
Sep 3, 2024 07:00AM PreveCeutical Engages Outside The Box Capital Inc. to Provide Marketing Services
Jul 9, 2024 07:00AM Preveceutical Announces Revocation of Management Cease Trade Order
Jun 28, 2024 06:17PM PreveCeutical Provides Update on Management Cease Trade Order
Jun 17, 2024 04:22PM PreveCeutical Enters into Loan Agreements
Jun 14, 2024 07:00AM PreveCeutical Provides Update on Management Cease Trade Order
Jun 6, 2024 07:00AM PreveCeutical Commences Litigation Against Former Legal Counsel in the British Columbia Supreme Court Alleging Professional Negligence
May 30, 2024 07:00AM Preveceutical Provides Update on Management Cease Trade Order
May 29, 2024 07:11PM Preveceutical Announces First Tranche Closing of Private Placement
May 16, 2024 08:32PM PreveCeutical Provides Update on Management Cease Trade Order
May 2, 2024 06:36PM PreveCeutical Announces Management Cease Trade Order
Dec 4, 2023 07:00AM PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
Sep 22, 2023 09:30AM New to The Street Announces its Five Corporate Interviews, airings on Newsmax and FOX Business Network
Sep 18, 2023 07:00AM PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
Sep 12, 2023 07:00AM PreveCeutical Showcases Dynamic Evolution in AI Strategy
Aug 31, 2023 07:00AM PreveCeutical Engages New to the Street for Production & Broadcasting Services
Jul 24, 2023 07:00AM PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia
Jun 28, 2023 07:00AM PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
May 30, 2023 07:00AM PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
Apr 24, 2023 07:00AM PreveCeutical Medical Launches Clinical Artificial Intelligence Division
Apr 20, 2023 07:00AM PreveCeutical Medical Announces Live Interactive Q&A Video Conference
Apr 4, 2023 07:00AM PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Mar 20, 2023 07:00AM PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Mar 6, 2023 07:00AM PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
Feb 21, 2023 07:00AM Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
Feb 7, 2023 11:48AM PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
Jan 25, 2023 07:00AM PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Jan 23, 2023 07:00AM PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Jan 17, 2023 07:00AM PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
Jan 12, 2023 06:00AM PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
Jan 9, 2023 07:00AM PreveCeutical Signs Intercompany Sol-Gel License Agreement
Nov 21, 2022 08:00AM PreveCeutical Files Application for D-amino Acid Peptides
Nov 11, 2022 07:30PM PreveCeutical Announces Conversion of Debt
Oct 20, 2022 08:00AM Appointment of Kathleen Rotika to PreveCeutical's Board of Directors
Sep 16, 2022 08:00PM PreveCeutical Announces Resignation of Board of Director Member
Sep 6, 2022 07:00AM Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
Jul 22, 2022 04:47PM PreveCeutical Enters into Credit Facility Agreement
May 27, 2022 04:30PM PreveCeutical Announces Change in Directors and Investor Awareness Services
May 9, 2022 08:00AM Article Based on PreveCeutical's Pain Management Peptides Program Published in the British Journal of Pharmacology
Mar 30, 2022 08:00PM PreveCeutical Announces Debt Settlement and Conversion of Debt
Jan 13, 2022 08:00AM Settlement Reached in Tietz Class Action Lawsuit
Nov 29, 2021 08:00AM PreveCeutical Files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral Use
Nov 24, 2021 08:00AM PreveCeutical Files Provisional Patent Application for D-Amino Acid Peptides
Nov 18, 2021 08:00AM PreveCeutical Signs License Agreement for Exclusive Rights to Use UniQuest's Sol-Gel Technology for Delivery of Cannabinoids
Oct 5, 2021 08:00AM Caroline MacCallum, MD, FRCPC, BSc Pharm, Joins PreveCeutical
Aug 31, 2021 08:00AM PreveCeutical Receives AU$315,338 Research & Development Tax Incentive Cash Refund
View More Recent Stories View Older Stories